Dimensional Fund Advisors LP Purchases 2,563,740 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Dimensional Fund Advisors LP increased its stake in Elanco Animal Health by 14.3%, owning approximately 20.5 million shares valued at around $214.9 million.
• Elanco's stock has received multiple upgrades from analysts, with a current average target price of $17.33 and a consensus rating of "Moderate Buy".
• In its latest quarterly earnings report, Elanco exceeded expectations with earnings of $0.26 per share and revenue of $1.24 billion, showcasing a year-over-year revenue increase of 4.8%.

Dimensional Fund Advisors LP increased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,464,727 shares of the company's stock after buying an additional 2,563,740 shares during the period. Dimensional Fund Advisors LP owned 4.12% of Elanco Animal Health worth $214,875,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Allworth Financial LP raised its stake in Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after purchasing an additional 2,090 shares during the last quarter. CoreCap Advisors LLC acquired a new position in Elanco Animal Health during the 4th quarter valued at $29,000. Parallel Advisors LLC raised its stake in Elanco Animal Health by 92.2% during the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after purchasing an additional 1,852 shares during the last quarter. NBC Securities Inc. acquired a new position in Elanco Animal Health during the 1st quarter valued at $40,000. Finally, Versant Capital Management Inc raised its stake in Elanco Animal Health by 65.9% during the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after purchasing an additional 1,740 shares during the last quarter. 97.48% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Stifel Nicolaus increased their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Piper Sandler raised their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, August 11th. Zacks Research cut shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Wednesday. Finally, Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective for the company in a research report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.33.

Elanco Animal Health Price Performance

ELAN traded up $0.4030 during midday trading on Friday, hitting $17.8930. The company had a trading volume of 6,722,648 shares, compared to its average volume of 6,667,397. The company has a market capitalization of $8.89 billion, a PE ratio of 20.81, a P/E/G ratio of 3.32 and a beta of 1.66. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $18.08. The firm's 50-day simple moving average is $15.08 and its 200-day simple moving average is $12.47.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.06. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company's revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.